Parathyroid hormone in osteoporosis

被引:2
作者
Cormier, C [1 ]
机构
[1] Hop Cochin, Serv Rhumatol A, APHP, F-75014 Paris, France
来源
PRESSE MEDICALE | 2006年 / 35卷 / 03期
关键词
D O I
10.1016/S0755-4982(06)74624-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Continuous parathyroid hormone secretion caused by primary hyperparathyroidism contributes to osteoporosis. Laboratory tests, in particular the intact PTH assay make the diagnosis of hyperparathyroidism, certain. In hyperparathyroidism, the bone damage primarily affects the cortical bone, especially the proximal one-third of the radius and to a lesser degree the upper femur, the lumbar spine is affected more rarely. Intermittent administration of parathyroid hormone stimulates bone formation and is useful in treating osteoporosis. Subcutaneous injections once daily administration of PTH stimulates bone formation on the surface of trabecular and cortical bone by preferential stimulation of osteoblastic more than osteoclastic activity.
引用
收藏
页码:495 / 501
页数:7
相关论文
共 39 条
[1]  
Adami S, 2002, J BONE MINER RES, V17, pN18
[2]   Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters [J].
Arlot, M ;
Meunier, PJ ;
Boivin, G ;
Haddock, L ;
Tamayo, J ;
Correa-Rotter, R ;
Jasqui, S ;
Donley, DW ;
Dalsky, GP ;
San Martin, J ;
Eriksen, EF .
JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (07) :1244-1253
[3]   Recommended testing in patients with low bone density [J].
Barzel, US .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (03) :1404-1405
[4]   Osteosarcoma of bone in a patient with primary hyperparathyroidism: A case report [J].
Betancourt, M ;
Wirfel, KL ;
Raymond, AK ;
Yasko, A ;
Lee, J ;
Vassilopoulou-Sellin, R .
JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 (01) :163-166
[5]  
Bilezikian JP, 2002, J BONE MINER RES, V17, pN2
[6]   Third- or second-generation parathyroid hormone assays: A remaining debate in the diagnosis of primary hyperparathyroidism [J].
Boudou, P ;
Ibrahim, F ;
Cormier, C ;
Chabas, C ;
Sarfati, E ;
Souberbielle, JC .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (12) :6370-6372
[7]   Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women [J].
Cosman, F ;
Nieves, J ;
Woelfert, L ;
Shen, V ;
Lindsay, R .
JOURNAL OF BONE AND MINERAL RESEARCH, 1998, 13 (06) :1051-1055
[8]   Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate [J].
Ettinger, B ;
San Martin, J ;
Crans, G ;
Pavo, I .
JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 (05) :745-751
[9]  
Glendenning P, 1998, AUST NZ J MED, V28, P173
[10]   Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiency [J].
Grey, A ;
Lucas, J ;
Horne, A ;
Gamble, G ;
Davidson, JS ;
Reid, IR .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (04) :2122-2126